中华肝脏外科手术学电子杂志
中華肝髒外科手術學電子雜誌
중화간장외과수술학전자잡지
CHINESE JOURNAL OF HEPATIC SURGERY(ELECTRONIC EDITION)
2014年
1期
46-51
,共6页
脂肪肝%大蒜%维生素类%枯否细胞%脂质过氧化作用
脂肪肝%大蒜%維生素類%枯否細胞%脂質過氧化作用
지방간%대산%유생소류%고부세포%지질과양화작용
Fatty liver%Garlic%Vitamins%Kupffer cells%Lipid peroxidation
目的：探讨大蒜素联合维生素C、维生素B6对小鼠非酒精性脂肪性肝病（NAFLD）的防治作用及其机制。方法18只C57BL/6小鼠按随机数字表法随机分成预防组、治疗组和对照组（各6只）。预防组：高脂饲料喂养的同时按体重给予大蒜素0.02 mg/g、维生素C 0.50 mg/g、维生素B60.02 mg/g，每天灌胃1次，连续4周。治疗组：在高脂饲料喂养4周后给予上述药物灌胃治疗1周。对照组：给予高脂饲料喂养4周，同时用等量生理盐水灌胃。处理结束后观察3组小鼠血清ALT、AST、游离脂肪酸（FFA）水平，肝组织超氧化物歧化酶（SOD）、丙二醛（MDA）水平，肝组织诱导型一氧化氮合酶（iNOS）表达及其信使核糖核酸（mRNA）含量，肝组织病理学改变及Kupffer细胞浸润情况。各组计量资料间比较采用单因素方差分析和LSD-t检验。结果预防组、治疗组、对照组小鼠血清ALT平均水平分别为（30±7）、（34±7）、（44±6）U/L，预防组和治疗组明显低于对照组（LSD-t=3.815，2.748；P<0.05）。预防组、治疗组、对照组小鼠血清AST水平分别为（46±6）、（43±8）、（103±7）U/L，预防组和治疗组明显低于对照组（LSD-t=12.400,16.371；P<0.05）。预防组、治疗组、对照组小鼠血清FFA水平分别为（196±10）、（223±12）、（254±31）mmol/L，预防组、治疗组明显低于对照组（LSD-t=4.335,2.271；P<0.05），且预防组明显低于治疗组（LSD-t=4.154, P<0.05）。预防组、治疗组、对照组小鼠肝组织SOD水平分别为（128±17）、（119±30）、（82±13）kU/L，预防组和治疗组明显高于对照组（LSD-t=5.413,2.850；P<0.05）。预防组、治疗组、对照组小鼠肝组织MDA水平分别为（5.5±1.9）（、5.7±1.9）（、7.9±0.9）μmol/L，预防组和治疗组明显低于对照组（LSD-t=2.818,2.527；P<0.05）。对照组小鼠肝组织iNOS蛋白表达较预防组和治疗组明显增强。预防组、治疗组、对照组小鼠肝组织iNOS mRNA含量分别为（3.6±0.5）×10-4，（3.3±0.5）×10-4，（7.5±0.3）×10-4，预防组和治疗组明显低于对照组（LSD-t=13.273,13.976；P<0.05）。对照组小鼠肝脏表现为明显脂肪肝，预防组和治疗组脂肪肝程度较轻。预防组和治疗组小鼠肝组织中的活化Kupffer细胞数量较对照组明显减少。结论大蒜素联合维生素C、维生素B6可有效防治小鼠NAFLD，其机制可能与减轻脂质过氧化损伤、增加肝脏抗氧化能力、抑制Kupffer细胞活性及降低血清FFA水平有关。
目的：探討大蒜素聯閤維生素C、維生素B6對小鼠非酒精性脂肪性肝病（NAFLD）的防治作用及其機製。方法18隻C57BL/6小鼠按隨機數字錶法隨機分成預防組、治療組和對照組（各6隻）。預防組：高脂飼料餵養的同時按體重給予大蒜素0.02 mg/g、維生素C 0.50 mg/g、維生素B60.02 mg/g，每天灌胃1次，連續4週。治療組：在高脂飼料餵養4週後給予上述藥物灌胃治療1週。對照組：給予高脂飼料餵養4週，同時用等量生理鹽水灌胃。處理結束後觀察3組小鼠血清ALT、AST、遊離脂肪痠（FFA）水平，肝組織超氧化物歧化酶（SOD）、丙二醛（MDA）水平，肝組織誘導型一氧化氮閤酶（iNOS）錶達及其信使覈糖覈痠（mRNA）含量，肝組織病理學改變及Kupffer細胞浸潤情況。各組計量資料間比較採用單因素方差分析和LSD-t檢驗。結果預防組、治療組、對照組小鼠血清ALT平均水平分彆為（30±7）、（34±7）、（44±6）U/L，預防組和治療組明顯低于對照組（LSD-t=3.815，2.748；P<0.05）。預防組、治療組、對照組小鼠血清AST水平分彆為（46±6）、（43±8）、（103±7）U/L，預防組和治療組明顯低于對照組（LSD-t=12.400,16.371；P<0.05）。預防組、治療組、對照組小鼠血清FFA水平分彆為（196±10）、（223±12）、（254±31）mmol/L，預防組、治療組明顯低于對照組（LSD-t=4.335,2.271；P<0.05），且預防組明顯低于治療組（LSD-t=4.154, P<0.05）。預防組、治療組、對照組小鼠肝組織SOD水平分彆為（128±17）、（119±30）、（82±13）kU/L，預防組和治療組明顯高于對照組（LSD-t=5.413,2.850；P<0.05）。預防組、治療組、對照組小鼠肝組織MDA水平分彆為（5.5±1.9）（、5.7±1.9）（、7.9±0.9）μmol/L，預防組和治療組明顯低于對照組（LSD-t=2.818,2.527；P<0.05）。對照組小鼠肝組織iNOS蛋白錶達較預防組和治療組明顯增彊。預防組、治療組、對照組小鼠肝組織iNOS mRNA含量分彆為（3.6±0.5）×10-4，（3.3±0.5）×10-4，（7.5±0.3）×10-4，預防組和治療組明顯低于對照組（LSD-t=13.273,13.976；P<0.05）。對照組小鼠肝髒錶現為明顯脂肪肝，預防組和治療組脂肪肝程度較輕。預防組和治療組小鼠肝組織中的活化Kupffer細胞數量較對照組明顯減少。結論大蒜素聯閤維生素C、維生素B6可有效防治小鼠NAFLD，其機製可能與減輕脂質過氧化損傷、增加肝髒抗氧化能力、抑製Kupffer細胞活性及降低血清FFA水平有關。
목적：탐토대산소연합유생소C、유생소B6대소서비주정성지방성간병（NAFLD）적방치작용급기궤제。방법18지C57BL/6소서안수궤수자표법수궤분성예방조、치료조화대조조（각6지）。예방조：고지사료위양적동시안체중급여대산소0.02 mg/g、유생소C 0.50 mg/g、유생소B60.02 mg/g，매천관위1차，련속4주。치료조：재고지사료위양4주후급여상술약물관위치료1주。대조조：급여고지사료위양4주，동시용등량생리염수관위。처리결속후관찰3조소서혈청ALT、AST、유리지방산（FFA）수평，간조직초양화물기화매（SOD）、병이철（MDA）수평，간조직유도형일양화담합매（iNOS）표체급기신사핵당핵산（mRNA）함량，간조직병이학개변급Kupffer세포침윤정황。각조계량자료간비교채용단인소방차분석화LSD-t검험。결과예방조、치료조、대조조소서혈청ALT평균수평분별위（30±7）、（34±7）、（44±6）U/L，예방조화치료조명현저우대조조（LSD-t=3.815，2.748；P<0.05）。예방조、치료조、대조조소서혈청AST수평분별위（46±6）、（43±8）、（103±7）U/L，예방조화치료조명현저우대조조（LSD-t=12.400,16.371；P<0.05）。예방조、치료조、대조조소서혈청FFA수평분별위（196±10）、（223±12）、（254±31）mmol/L，예방조、치료조명현저우대조조（LSD-t=4.335,2.271；P<0.05），차예방조명현저우치료조（LSD-t=4.154, P<0.05）。예방조、치료조、대조조소서간조직SOD수평분별위（128±17）、（119±30）、（82±13）kU/L，예방조화치료조명현고우대조조（LSD-t=5.413,2.850；P<0.05）。예방조、치료조、대조조소서간조직MDA수평분별위（5.5±1.9）（、5.7±1.9）（、7.9±0.9）μmol/L，예방조화치료조명현저우대조조（LSD-t=2.818,2.527；P<0.05）。대조조소서간조직iNOS단백표체교예방조화치료조명현증강。예방조、치료조、대조조소서간조직iNOS mRNA함량분별위（3.6±0.5）×10-4，（3.3±0.5）×10-4，（7.5±0.3）×10-4，예방조화치료조명현저우대조조（LSD-t=13.273,13.976；P<0.05）。대조조소서간장표현위명현지방간，예방조화치료조지방간정도교경。예방조화치료조소서간조직중적활화Kupffer세포수량교대조조명현감소。결론대산소연합유생소C、유생소B6가유효방치소서NAFLD，기궤제가능여감경지질과양화손상、증가간장항양화능력、억제Kupffer세포활성급강저혈청FFA수평유관。
Objective To study the role of garlicin, vitamin C and vitamin B6 and the mechanism in preventing and treating non-alcoholic fatty liver disease (NAFLD) in mouse. Methods Eighteen C57BL/6 mice were randomly divided into 3 groups according to the random number table:preventing group, treating group and control group with 6 mice in each group. In preventing group, the mice were fed with high fatty diet and were infused intragastrically with garlicin (0.02 mg/g), vitamin C (0.50 mg/g) and vitamin B6 (0.02 mg/g) by weight everyday at the same time for 4 weeks. In treating group, the mice were infused intragastrically with the above drugs for 1 week after 4 weeks of feeding with high fatty diet. In control group, the mice were fed with high fatty diet and were infused intragastrically with equivalent normal saline at the same time for 4 weeks. After processing, the levels of serum alanine aminotransferase (ALT), aspartate aminotransferase (AST), free fatty acids (FFA), levels of superoxide dismutase (SOD), malondialdehyde (MDA), expression of inducible nitric oxide synthase (iNOS), content of messenger ribonucleic acid (mRNA) of iNOS, pathological changes and inifltration of Kupffer cells of liver tissues in 3 groups were observed. The differences of measurement data in 3 groups were compared using one-way analysis of variance and LSD-t test. Results The mean levels of serum ALT were (30±7), (34±7), (44±6) U/L in preventing group, treating group and control group respectively, which were signiifcantly lower in preventing group and treating group than that in control group (LSD-t=3.815, 2.748; P<0.05). The levels of serum AST were (46±6), (43±8), (103±7) U/L in preventing group, treating group and control group respectively, which were significantly lower in preventing group and treating group than that in control group (LSD-t=12.400, 16.371; P<0.05). The levels of serum FFA were (196±10), (223±12), (254±31) mmol/L in preventing group, treating group and control group respectively, which were signiifcantly lower in preventing group and treating group than that in control group (LSD-t=4.335, 2.271; P<0.05), and it was significantly lower in preventing group than that in treating group (LSD-t=4.154;P<0.05). The levels of serum SOD were (128±17), (119±30), (82±13) kU/L in preventing group, treating group and control group respectively, which were signiifcantly higher in preventing group and treating group than that in control group (LSD-t=5.413, 2.850; P<0.05). The levels of serum MDA were (5.5±1.9), (5.7±1.9), (7.9±0.9)μmol/L in preventing group, treating group and control group respectively, which were signiifcantly lower in preventing group and treating group than that in control group (LSD-t=2.818, 2.527; P<0.05). The expression of iNOS protein in liver tissues of mice in control group signiifcantly increased, compared with that in preventing group and treating group. The mRNA contents of iNOS in liver tissues of mice were (3.6±0.5)×10-4, (3.3±0.5)×10-4, (7.5±0.3)×10-4, which were signiifcantly lower in preventing group and treating group than that in control group (LSD-t=13.273, 13.976; P<0.05). Obvious fatty liver was observed in mice of control group, while it was milder in preventing group and treating group. The activated Kupffer cells in liver tissues significantly decreased in preventing group and treating group, compared with that in control group. Conclusions Combined use of garlicin, vitamin C and vitamin B6 is effective in preventing and treating NAFLD. The mechanism may be related with alleviating lipid peroxidation damage, enhancing the oxidation resistance of liver, suppressing cytoactive of Kupffer cells and decreasing the levels of serum FFA.
